Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ponesimod - Janssen Pharmaceuticals

Drug Profile

Ponesimod - Janssen Pharmaceuticals

Alternative Names: ACT-128800; Compound 8bo - Actelion; PONVORY; R-3477; RG 3477

Latest Information Update: 15 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Actelion Pharmaceuticals; Janssen Pharmaceuticals
  • Class Antipsoriatics; Chlorobenzenes; Imines; Phenyl ethers; Small molecules; Thiazolidines
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • No development reported Graft-versus-host disease
  • Discontinued Plaque psoriasis

Most Recent Events

  • 13 Oct 2021 Updated efficacy data from the phase III OPTIMUM trial in Multiple sclerosis released by Janssen pharmaceuticals
  • 29 Sep 2021 Launched for Multiple sclerosis in USA (PO) - First Global Launch before September 2021
  • 25 May 2021 Registered for Multiple sclerosis in European Union, Iceland, Norway, Liechtenstein (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top